Summary

Eligibility
for males ages 18 years and up (full criteria)
Location
at UC Irvine UCLA UCSF
Dates
study started
completion around

Description

Summary

Official Title

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer

Keywords

Biochemically Recurrent Prostate Cancer, darolutamide, high risk BCR, PSMA PET imaging, Prostatic Neoplasms, Darolutamide (BAY1841788, Nubeqa), ADT, Darolutamide+ADT

Eligibility

Locations

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bayer
Links
Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.
ID
NCT05794906
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 750 study participants
Last Updated